Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability

Source :: PR Newswire. November 4, 2013
Publication Year :: 2013
Abstract: 'RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Patients' TSX Exchange Symbol: RVX CALGARY, Nov. 4, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced two [...]

Subjects :: Cholesterol
Inflammation
Clinical trials
Business
News, opinion and commentary

Tools